Found 696 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
The primary purpose of this study is to evaluate the pulse wave velocity and vascular compliance measurements at the beginning and the end of the study while the patient is taking either Envarsus XR® (extended release tacrolimus) tablets administered once-daily after transplantation or immediate release generic tacrolimus capsules that are …
In the past, clinical trials on cutaneous lupus erythematosus (CLE) have not used patient-reported outcome measures to evaluate treatment efficacy; however, recent studies with small numbers of patients with CLE have compared questionnaires before and after treatment. Overall, there is little data available on changes in patient-reported outcome measures in …
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
Please see the Study Description, Section 1.1 of the Protocol.
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
Use of an HIV+ deceased donor could increase the risk of death, transplant-related or HIV-related complications; alternatively with effective antiretroviral treatment and careful HIV+ donor selection, these risks may be comparable to kidney transplant using an HIV-negative donor. We hypothesize that receiving a kidney transplant from an HIV+ donor will …
A 28-week research study is being conducted that is designed to help all participants lose weight. All participants will receive lifestyle modification (diet, exercise, and behavioral treatment). Participants who do not lose weight with lifestyle modification alone also will be prescribed an FDA-approved weight loss medication (phentermine) or placebo.
The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive …
